Anemia and inflammatory bowel disease;Anemia y enfermedad inflamatoria intestinal

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 5, 2008, Pages 285-293

  De La Morena López, Felipe ^a,c   Gisbert, J P ^b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c NONE   (Spain)

Author keywords

Anemia; Inflammatory bowel disease; Iron deficiency

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; HEMOGLOBIN; IRON; IRON DEXTRAN;

ANEMIA; CLINICAL FEATURE; ENTERITIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; MALNUTRITION; PREVALENCE; REVIEW; TREATMENT INDICATION; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; ARTICLE; DECISION TREE; IRON DEFICIENCY ANEMIA;

ANEMIA, IRON-DEFICIENCY; DECISION TREES; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 47049109114     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Gasche C. Anemia in IBD: The overlooked villain. Inflamm Bowel Dis 2000; 6 (2): 142-50; discussion 51.
2. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53 (8): 1190-7.
3. Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, Howell JB, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 (1): 47-52.
4. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12 (2): 123-30.
5. Kulnigg S, Gasche C. Systematic review: Managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24 (11-12): 1507-23.
6. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 2001; 7 (3): 250-5.
7. Freire WB. Iron-deficiency anemia: PAHO/WHO strategies to fight it. Salud Publica Mex 1998; 40 (2): 199-205.
8. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am J Med 2004; 116 (Supl. 7A): 1S-2S.
9. Frewin R, Henson A, Provan D. ABC of clinical haematology. Iron deficiency anaemia. BMJ 1997; 314 (7077): 360-3.
10. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80 (7): 1639-47.
11. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 2004; 116 (Supl. 7A): 44S-9S.
12. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990; 38 (3): 480-6.
13. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100 (11): 2503-9.
14. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: Double blind randomised placebo controlled trial. BMJ 2003; 326 (7399): 1124.
15. Vijverman A, Piront P, Belaiche J, Louis E. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg 2006; 69 (1): 1-4.
16. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001; 96 (8): 2296-8.
17. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978; 13 (6): 649-56.
18. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000; 46 (Supl. 3-4): IV1-IV5.
19. Thomson AB, Brust R, Ali MA, Mant MJ, Valberg LS. Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin. Am J Dig Dis 1978; 23 (8): 705-9.
20. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996; 93 (16): 8175-82.
21. Ponka P. Cellular iron metabolism. Kidney Int Suppl 1999; 69: S2-11.
22. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 1992; 119 (4): 385-90.
23. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48 (7): 1066-76.
24. Guagnozzi D, Severi C, Ialongo P, Viscido A, Patrizi F, Testino G, et al. Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis 2006; 12 (2): 150-1.
25. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007; 13 (36): 4798-806.
26. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Haematol 2002; 15 (2): 399-409.
27. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102 (3): 783-8.
28. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007; 132 (1): 294-300.
29. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006; 12 (12): 1101-6.
30. Graziadei I, Gaggl S, Kaserbacher R, Braunsteiner H, Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming unitserythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 1994; 83 (1): 260-8.
31. Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995; 162 (1): 134-8.
32. Maciejewski JP, Selleri C, Sato T, Cho HJ, Keefer LK, Nathan CF, et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 1995; 96 (2): 1085-92.
33. Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, et al. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994; 39 (9): 1930-4.
34. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79 (8): 1987-94.
35. Hvas AM, Nexo E. Diagnosis and treatment of vitamin B12 deficiency - an update. Haematologica 2006; 91 (11): 1506-12.
36. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28 (9): 833-42.
37. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34 (4): 738-46.
38. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: A review. J R Soc Med 1992; 85 (12): 752-6.
39. Gisbert JP, Luna M, Mate J, González-Guijarro L, Cara C, Pajares JM. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 2003; 121 (1): 1-5.
40. Gisbert JP, González-Lama Y, Mate J. Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol Hepatol 2006; 29 (9): 568-83.
41. Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, et al. Thiopurine methyltransferase activity in Spain: A study of 14,545 patients. Dig Dis Sci 2007; 52 (5): 1262-9.
42. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135 (3): 256-62.
43. Manosa M, Doménech E, Sánchez-Delgado J, Bernal I, García-Planella E, Gassull MA. Autoimmune hemolytic anemia associated with ulcerative colitis. Gastroenterol Hepatol 2005; 28 (5): 283-4.
44. Buelta-González C, Fernández-Salazar L, Martín-Merino M, Aller de la Fuente R, Cuello García R. Ulcerative colitis and autoimmune hemolytic anemia. Gastroenterol Hepatol 2006; 29 (2): 110.
45. Lorber M, Schwartz LI, Wasserman LR. Association of antibody-coated red blood cells with ulcerative colitis; report of four cases. Am J Med 1955; 19 (6): 887-94.
46. Giannadaki E, Potamianos S, Roussomoustakaki M, Kyriakou D, Fragkiadakis N, Manousos ON. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol 1997; 92 (10): 1872-4.
47. Yates P, Macht LM, Williams NA, Elson CJ. Red cell autoantibody production by colonic mononuclear cells from a patient with ulcerative colitis and autoimmune haemolytic anaemia. Br J Haematol 1992; 82 (4): 753-6.
48. Ng JP, Soliman A, Kumar B, Lam DC. Auto-immune haemolytic anaemia and Crohn's disease: A case report and review of the literature. Eur J Gastroenterol Hepatol 2004; 16 (4): 417-9.
49. Kraus J, Schneider R. Pernicious anemia caused by Crohn's disease of the stomach. Am J Gastroenterol 1979; 71 (2): 202-5.
50. Koutroubakis IE, Karmiris K, Kouroumalis EA. Treatment of anaemia in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23 (8): 1273-4; author reply 4-5.
51. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39 (5): 454-8.
52. Doménech E, Manosa M, Masnou H, Navarro M, García-Planella E, Bernal I, et al. Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 2005; 100 (2): 496.
53. Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Iron and inflammatory bowel disease. Aliment Pharmacol Ther 2001; 15 (4): 429-38.
54. Rockey DC. Treatment of iron deficiency. Gastroenterology 2006; 130 (4): 1367-8.
55. Rimon E, Kagansky N, Kagansky M, Mechnick L, Mashiah T, Namir M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med 2005; 118 (10): 1142-7.
56. Zlotkin S, Arthur P, Antwi KY, Yeung G. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics 2001; 108 (3): 613-6.
57. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM. Efficacy and tolerability of low-dose iron supplements during pregnancy: A randomized controlled trial. Am J Clin Nutr 2003; 78 (1): 145-53.
58. Gasche C, Dejaco C, Reinisch W, Tillinger W, Waldhoer T, Fueger GF, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60 (3): 262-7.
59. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: A prospective, comparative trial. Aliment Pharmacol Ther 2005; 22 (11-12): 1097-105.
60. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: Usage, tolerance, and efficacy. Inflamm Bowel Dis 2003; 9 (5): 316-20.
61. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003; 38 (5): 543-8.
62. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22 (9): 831-8.
63. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40 (9): 1058-65.
64. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76 (1): 74-8.
65. Allen LH. Iron supplements: Scientific issues concerning efficacy and implications for research and programs. J Nutr 2002; 132 (Supl. 4): 813S-9S.
66. Schroder O, Schrott M, Blumenstein I, Jahnel J, Dignass AU, Stein J. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol 2004; 42 (8): 663-7.
67. Ifudu O. Parenteral iron: Pharmacology and clinical use. Nephron 1998; 80 (3): 249-56.
68. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61 (5): 1830-9.
69. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13 (6): 381-4.
70. Gordeuk VR, Brittenham GM, Bravo J, Hughes MA, Keating LJ. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion 1990; 30 (3): 239-45.
71. Mei Z, Cogswell ME, Parvanta I, Lynch S, Beard JL, Stoltzfus RJ, et al. Hemoglobin and ferritin are currently the most efficient indicators of population response to iron interventions: An analysis of nine randomized controlled trials. J Nutr 2005; 135 (8): 1974-80.
72. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96 (8): 2382-7.
73. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316 (2): 73-8.
74. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991; 78 (10): 2564-7.
75. Dohil R, Hassall E, Wadsworth LD, Israel DM. Recombinant human erythropoietin for treatment of anemia of chronic disease in children with Crohn's disease. J Pediatr 1998; 132 (1): 155-9.
76. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126 (10): 782-7.
77. Demirturk L, Hulagu S, Yaylaci M, Altin M, Ozel M. Serum erythropoietin levels in patients with severe anemia secondary to inflammatory bowel disease and the use of recombinant human erythropoietin in patients with anemia refractory to treatment. Dis Colon Rectum 1995; 38 (8): 896-7.
78. Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: A pilot study. Eur J Gastroenterol Hepatol 2006; 18 (4): 421-5.
79. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334 (10): 619-23.
80. Horina JH, Petritsch W, Schmid CR, Reicht G, Wenzl H, Silly H, et al. Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: Results in three patients. Gastroenterology 1993; 104 (6): 1828-31.
81. Sandborn W. Erythropoietin for inflammatory bowel disease anemia. Gastroenterology 1997; 112 (2): 660-1.